Dysregulation of the TSHR underpins multiple thyroid‐related pathologies, including GD, GO, hypothyroidism, and thyroid cancer, positioning TSHR as a high‐value therapeutic target.[12] Over the past decades, various TSHR inhibitors such as small molecules, monoclonal antibodies, and peptides have emerged.[12, 31, 32] However, most exhibit suboptimal characteristics like inadequate potency, off‐target effects, and poor pharmacokinetics. The gene discussed is TSHR; the disease is hypothyroidism.